\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\ \(73\)\
\-\ surgery\\ followed\\ by\\ radiation\\ therapy\ \(1\)\
\-\ enhancing\\,\\ relatively\\ homogeneous\\,\\ cerebellar\\ mass\\.\ \(0\)\
\-\ compression\\ of\\ 4th\\ ventricle\\ with\\ supratentorial\\ obstructive\\ hydrocephalus\\.\ \(0\)\
\-\ medulloblastoma\ \(30\)\
\-\ \\â\\€\\¢\\ pnet\ \(0\)\
\-\ \\â\\€\\¢\\ ependymoma\ \(8\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ 31\\ y\\.o\\.\\ woman\\ presents\\ with\\ diplopia\\ and\\ ataxia\\.\ \(1\)\
\-\ initial\\ clinical\\ diagnosis\\ was\\ ms\ \(0\)\
\-\ most\\ medulloblastomas\\ \\-\\ about\\ 60\\%\\,\\ present\\ during\\ the\\ first\\ two\\ decades\\.\\ \\ however\\,\\ as\\ in\\ this\\ case\\,\\ about\\ 1\\/3\\ of\\ patients\\ present\\ over\\ the\\ age\\ of\\ fifteen\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ medulloblastomas\\:\\ 0\\.09768235614301757\ \(0\)\
\-\ fifteen\\:\\ 0\\.09121620900673921\ \(0\)\
\-\ about\\:\\ 0\\.0833938609140317\ \(0\)\
\-\ 1\\/3\\:\\ 0\\.07034711248031665\ \(0\)\
\-\ supratentorial\\:\\ 0\\.06986938680964772\ \(0\)\
\-\ decades\\:\\ 0\\.0694090368834341\ \(0\)\
\-\ pnet\\:\\ 0\\.06554344638278624\ \(0\)\
\-\ diplopia\\:\\ 0\\.06312502566427093\ \(0\)\
\-\ medulloblastoma\\:\\ 0\\.06285279521843595\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.05950687411123625\ \(0\)\
\-\ ataxia\\:\\ 0\\.05781042002426758\ \(0\)\
\-\ ms\\:\\ 0\\.05781042002426758\ \(0\)\
\-\ 31\\:\\ 0\\.05676943143898946\ \(0\)\
\-\ obstructive\\:\\ 0\\.05565414957177089\ \(0\)\
\-\ 4th\\:\\ 0\\.05448935338543859\ \(0\)\
\-\ homogeneous\\:\\ 0\\.0512004278417827\ \(0\)\
\-\ present\\:\\ 0\\.04886098111219445\ \(0\)\
\-\ ependymoma\\:\\ 0\\.04841880806566787\ \(0\)\
\-\ 60\\:\\ 0\\.047188887199166\ \(0\)\
\-\ cerebellar\\:\\ 0\\.04665341403852436\ \(0\)\
\-\ hydrocephalus\\:\\ 0\\.04650449199321314\ \(0\)\
\-\ relatively\\:\\ 0\\.04628434335129075\ \(0\)\
\-\ ventricle\\:\\ 0\\.04053658629846111\ \(0\)\
\-\ compression\\:\\ 0\\.0404904724848092\ \(0\)\
\-\ available\\:\\ 0\\.0363635322637949\ \(0\)\
\-\ first\\:\\ 0\\.03629725866817535\ \(0\)\
\-\ followed\\:\\ 0\\.03626425153644015\ \(0\)\
\-\ initial\\:\\ 0\\.035842811940244405\ \(0\)\
\-\ radiation\\:\\ 0\\.035496851260282736\ \(0\)\
\-\ enhancing\\:\\ 0\\.03392346244157923\ \(0\)\
\-\ clinical\\:\\ 0\\.03328240253248107\ \(0\)\
\-\ during\\:\\ 0\\.03310138291042795\ \(0\)\
\-\ age\\:\\ 0\\.03292291551321907\ \(0\)\
\-\ y\\.o\\:\\ 0\\.031219992817553166\ \(0\)\
\-\ two\\:\\ 0\\.03097887642551906\ \(0\)\
\-\ however\\:\\ 0\\.030118582982241397\ \(0\)\
\-\ therapy\\:\\ 0\\.028919503749881177\ \(0\)\
\-\ patients\\:\\ 0\\.02799461518184843\ \(0\)\
\-\ over\\:\\ 0\\.02753977962202484\ \(0\)\
\-\ metastatic\\:\\ 0\\.0272292329571657\ \(0\)\
\-\ surgery\\:\\ 0\\.026265810941269303\ \(0\)\
\-\ \\%\\:\\ 0\\.025231911814506427\ \(0\)\
\-\ woman\\:\\ 0\\.024986113259353245\ \(0\)\
\-\ most\\:\\ 0\\.02497259673073514\ \(0\)\
\-\ diagnosis\\:\\ 0\\.02483821937696734\ \(0\)\
\-\ case\\:\\ 0\\.023664613074269248\ \(0\)\
\-\ \\-\\:\\ 0\\.023186436186181818\ \(0\)\
\-\ presents\\:\\ 0\\.022096763234277544\ \(0\)\
\-\ by\\:\\ 0\\.018011024091707274\ \(0\)\
\-\ disease\\:\\ 0\\.017680222040705115\ \(0\)\
\-\ \\,\\:\\ 0\\.01713354845046123\ \(0\)\
\-\ as\\:\\ 0\\.016361740580938325\ \(0\)\
\-\ not\\:\\ 0\\.01563061609799918\ \(0\)\
\-\ mass\\:\\ 0\\.015043810214526132\ \(0\)\
\-\ was\\:\\ 0\\.012509842053337808\ \(0\)\
\-\ this\\:\\ 0\\.012166293839419405\ \(0\)\
\-\ in\\:\\ 0\\.0053341421536741125\ \(0\)\
\-\ of\\:\\ 0\\.004424194967012219\ \(0\)\
\-\ the\\:\\ 0\\.0034999818912310326\ \(0\)\
\-\ with\\:\\ 0\\.002962131040250373\ \(0\)\
\-\ \\.\\:\\ 0\\.0026961672985326285\ \(0\)\
\-\ and\\:\\ 0\\.002278595009268588\ \(0\)\
